section name header

Pronunciation

PRI-mi-done

Classifications

Therapeutic Classification: anticonvulsants

Indications

BEERS REMS

Unlabeled Uses:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 80–100% absorbed from the GI tract when administered orally.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Converted to phenobarbital and another active anticonvulsant compound by the liver.

Half-life: 3–7 hr.

Time/Action Profile

(anticonvulsant effect)

ROUTEONSETPEAKDURATION
PO4–7 days7–10 days8–12 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, orthostatic hypotension.

Derm: alopecia, rash.

EENT: visual changes.

GI: anorexia, hepatitis, nausea, vomiting.

Hemat: blood dyscrasias, folic acid deficiency, megaloblastic anemia.

Neuro: ataxia, drowsiness, vertigo, excitement ( in children), SUICIDAL THOUGHTS.

Resp: dyspnea.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations: Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Mysoline